Background Diabetes is a multisystem disorder associated with a nearly twofold excess risk
for a broad range of adverse cardiovascular outcomes including coronary heart disease …

OBJECTIVE The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular
Outcome Results (LEADER) trial (ClinicalTrials. gov reg. no. NCT01179048) demonstrated a …

Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue,
when added to standard care in patients with type 2 diabetes, remains unknown. Methods In …

Background: The glucagon-like peptide-1 analog liraglutide reduced cardiovascular events
and mortality in patients with type 2 diabetes mellitus in the LEADER trial (Liraglutide and …

We assessed the cardiovascular safety of liraglutide, a glucagon-like peptide-1 receptor
agonist, using existing clinical data. Patient-level results from all completed phase 2 and 3 …

On January 25, the FDA approved liraglutide, a glucagon-like-peptide-1 receptor agonist
that can improve glycemic control in adults with type 2 diabetes. Drs. Mary Parks and Curtis …

Importance After the occurrence of nonfatal cardiovascular events, recurrent events are
highly likely. Most cardiovascular outcomes trials analyze first events only; extending …

Liraglutide is a new glucagon‐like peptide‐1 (GLP‐1) receptor agonist and a true GLP‐1
analogue. After successful phase 2 studies, liraglutide was assessed in a series of phase 3 …

Type 2 diabetes is characterized by a progressive decline in beta cell function, with
consequent worsening of glycemic control. The ideal antihyperglycemic treatment should …

Background More data regarding effects of glucagon-like peptide-1 receptor agonists in
patients with type 2 diabetes (T2D) and heart failure (HF) are required. Objectives The …